Princeton-based Soligenix Inc. announced on Monday the appointment of Diane Parks to its board of directors.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Parks, a veteran pharmaceutical executive, served most recently as senior vice president and head of U.S. Commercial for Kite Pharma Inc. Prior to that, she served as vice president and head of global marketing for Pharmacyclics Inc. Parks also previously served as vice president of sales for Amgen Inc. and as senior vice president, specialty biotherapeutics for Genentech Inc.
“As Soligenix looks forward to potential product approval, we intend to leverage Ms. Park’s extensive business and commercialization experience in launching novel drug therapies in orphan diseases and areas of high unmet medical need. We believe her expertise will add significantly to our already diverse and experienced board of directors and management team,” said Christopher Schaber, president and chief executive officer of Soligenix, in a statement.
“We welcome her counsel and look forward to her contributions to our future success, especially as we look to complete our pivotal Phase 3 clinical trials of SGX301 for the treatment of cutaneous T-cell lymphoma and SGX942 for the treatment of oral mucositis in head and neck cancer patients,” he added.
Parks also currently on the boards of Calliditas Therapeutics AB and Healogix LLC.
“I am truly excited to be joining the Soligenix board of directors at such an important time in the Company’s life cycle,” said Parks. “Having spent the majority of my career successfully building commercial teams and launching a number of unique drugs in the biotech and pharmaceutical industry, I am quite excited to contribute to Soligenix as they begin to position themselves for potential success with their rare disease pipeline.
“I believe Soligenix has the potential for significant value creation with commercialization of its rare disease pipeline. I look forward to working closely with the board and management team to maximize that potential,” she said.